The Chinese are paying $313 mill or 14.7x forward EBITDA for VIT, based on forward EBITDA of $21 mill.
Analysts consensus expect BAL to do approx $90 mill EBITDA in 2017, which at 14.7x would price them at $1.323 bill or $13.80 a share. However, given that their EBITDA estimate is 4.5x that of VIT, we should apply at least a 10% premium on any T/O price for BAL, which would value BAL at $15.20.
We have some way to go, and bearing in mind that there is 10% currently short, and only 96 mill shares on issue, this could get really, REALLY interesting.
- Forums
- ASX - By Stock
- BAL
- vitaco takeover
vitaco takeover, page-2
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online